Division of Boston Scientific Corp.
Latest From Guidant Corp.
Five-year mortality and major morbidity results from a large randomized trial run by the Veterans Affairs found no advantages to so-called off-pump "beating heart" coronary bypass graft surgery over traditional on-pump bypass surgery in which the patient is supported by a cardiopulmonary bypass machine.
The decision is a coda to a 2014 Federal Circuit verdict that an implantable cardioverter defibrillator patent held by Mirowski Family Ventures was invalid. About $6m in attorney’s fees were at stake.
Boston Scientific will have to pay up $308m to a patent licensor after the US Supreme Court rejected the firm's petition to hear its case.
2016 was a year of surprise and change in political circles, but that's nothing new for the medtech industry, which over a number of years has become accustomed to health care systems demanding different and ever-higher levels of service. Smart medtechs have been ahead of the curve, but the whole industry now factors in clients' wider needs in a holistic approach to patient care. Many companies' current M&A policies are already reflecting the changes to come.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Site Specific
- Drug Delivery
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Boston Scientific Corp.
- Senior Management
- Keith Brauer, VP, Fin. & CFO
- Contact Info
Phone: (317) 971-2000
111 Monument Cir.
P.O. Box 44906 Indianapolis, IN 46204-5129
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.